An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-Week Course of PEG-Interferon Alpha-2b Versus a 12-Week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C.
Phase of Trial: Phase III
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 07 Jun 2017 Biomarkers information updated
- 18 Jan 2014 Results published in the Hepatology.
- 30 Jan 2012 Actual patient number changed from 137 to 130 as reported by ClinicalTrials.gov.